<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0187-893X</journal-id>
<journal-title><![CDATA[Educación química]]></journal-title>
<abbrev-journal-title><![CDATA[Educ. quím]]></abbrev-journal-title>
<issn>0187-893X</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Química]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0187-893X2016000400286</article-id>
<article-id pub-id-type="doi">10.1016/j.eq.2016.07.002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La nanomedicina y los sistemas de liberación de fármacos: ¿la (r)evolución de la terapia contra el cáncer?]]></article-title>
<article-title xml:lang="en"><![CDATA[Nanomedicine and drug delivery systems: the (r)evolution of cancer therapy?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas-Aguirre]]></surname>
<given-names><![CDATA[Yareli]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguado-Castrejón]]></surname>
<given-names><![CDATA[Karina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Méndez]]></surname>
<given-names><![CDATA[Israel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Química Departamento de Farmacia]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>27</volume>
<numero>4</numero>
<fpage>286</fpage>
<lpage>291</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0187-893X2016000400286&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0187-893X2016000400286&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0187-893X2016000400286&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[El término nanotecnología hace referencia a una serie de disciplinas que estudian y manipulan la materia a nivel de la nanoescala. Una de las áreas más importantes de la nanotecnología es la nanomedicina, la cual está enfocada en gran medida en el diseño de nanosistemas de liberación de fármacos que prometen revolucionar las terapias convencionales, especialmente aquellas dirigidas al tratamiento del cáncer. En este trabajo se presentan los aspectos fundamentales de la nanomedicina y el desarrollo de nanoacarreadores de fármacos anticancerígenos, así como los retos y las perspectivas a considerar para que las nanoterapias se conviertan en una realidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[The term nanotechnology refers to a number of disciplines intended to study materials and structures at the nanoscale. One of the most important areas of nanotechnology is nanomedicine, which is focused in great extent on the design and development of drug delivery systems. These drug delivery platforms can display very sophisticated properties and unique features, and are considered as the revolution of the conventional chemotherapies, specifically those to treat cancer. In this work we review the concept of nanomedicine and its application on the design of nanocarriers of antineoplastic drugs and highlight some aspects that have to be addressed to translate the drug delivery platforms in to devices with possibilities to reach clinical trials.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Nanotecnología]]></kwd>
<kwd lng="es"><![CDATA[Liberación de fármacos]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="en"><![CDATA[Nanotechnology]]></kwd>
<kwd lng="en"><![CDATA[Drug delivery]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<source><![CDATA[Abraxane]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhuang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2016</year>
<volume>235</volume>
<page-range>182-94</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Doxil® &#8212;The first FDA-approved nano-drug: Lessons learned]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barenholz]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2012</year>
<volume>160</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>117-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<source><![CDATA[Cuadro básico de medicamentos]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawidczyk]]></surname>
<given-names><![CDATA[C.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[L.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[K.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Pomper]]></surname>
<given-names><![CDATA[M.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2014</year>
<volume>187</volume>
<page-range>133-44</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The dawning era of polymer therapeutics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature Reviews. Drug Discovery]]></source>
<year>2003</year>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>347-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nanomedicine(s) under the Microscope]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecular Pharmaceutics]]></source>
<year>2011</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2101-41</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer nanotechnology: Opportunities and challenges]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature Reviews Cancer]]></source>
<year>2005</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>161-71</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hallmarks of cancer: Of all cancer cells, all the time?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Floor]]></surname>
<given-names><![CDATA[S.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Dumont]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Maenhaut]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Raspe]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends in Molecular Medicine]]></source>
<year>2012</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>509-15</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[What is nanomedicine?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nanomedicine: Nanotechnology, Biology and Medicine]]></source>
<year>2005</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<source><![CDATA[Incan-mexico.org]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Imaging and drug delivery using theranostic nanoparticles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janib]]></surname>
<given-names><![CDATA[S.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Moses]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[MacKay]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Advanced Drug Delivery Reviews]]></source>
<year>2010</year>
<volume>62</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1052-63</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Combo&#8221; nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kemp]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Shim]]></surname>
<given-names><![CDATA[M.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Heo]]></surname>
<given-names><![CDATA[C.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[Y.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Advanced Drug Delivery Reviews.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mansour]]></surname>
<given-names><![CDATA[H.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Blough]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nanomedicine in drug delivery]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Boca Raton FL ]]></publisher-loc>
<publisher-name><![CDATA[CRC Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer targeted therapeutics: From molecules to drug delivery vehicles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Auguste]]></surname>
<given-names><![CDATA[D.T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2015</year>
<volume>219</volume>
<page-range>632-43</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delivery of drugs to intracellular organelles using drug delivery systems: Analysis of research trends and targeting efficiencies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maity]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Stepensky]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[International Journal of Pharmaceutics]]></source>
<year>2015</year>
<volume>496</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>268-74</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer nanotechnology: Application of nanotechnology in cancer therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Acharya]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sahoo]]></surname>
<given-names><![CDATA[S.K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Discovery Today]]></source>
<year>2010</year>
<volume>15</volume>
<page-range>842-50</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Doxorubicin induced heart failure: Phenotype and molecular mechanisms]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitry]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[IJC Heart &amp; Vasculature]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>17-24</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nanotheranostics for personalized medicine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mura]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Couvreur]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Advanced Drug Delivery Reviews]]></source>
<year>2012</year>
<volume>64</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1394-416</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stimuli-responsive nanocarriers for drug delivery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mura]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Couvreur]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature Materials]]></source>
<year>2013</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>991-1003</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="">
<source><![CDATA[National Nanotechn, National Nanotechnology Initiative]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torchilin]]></surname>
<given-names><![CDATA[V.P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature Reviews. Drug Discovery]]></source>
<year>2014</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>813-27</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wicki]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Witzigmann]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Balasubramanian]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Huwyler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2015</year>
<volume>200</volume>
<page-range>138-57</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: A meta-analysis of ten randomized controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[PloS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e0133569</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nanomedicine of synergistic drug combinations for cancer therapy &#8212;Strategies and perspectives]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[R.X.]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[H.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[H.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Eoh]]></surname>
<given-names><![CDATA[J.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X.Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Controlled Release]]></source>
<year>2016</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
